In a significant development for Durect Corporation (NASDAQ: DRRX), the U.S. Food and Drug Administration (FDA) has approved the company’s plan for a pivotal Phase 3 trial to test larsucosterol, a promising treatment for severe alcohol-associated hepatitis (AH). This approval promises to streamline the drug’s development pathway, potentially speeding up its availability to patients in need.
Durect’s planned study will enroll 200 patients across the United States to evaluate the efficacy of larsucosterol, with a primary focus on 90-day mortality rates. This design follows notable findings from the Phase 2 AHFIRM study, during which the treatment demonstrated a remarkable 60% reduction in mortality among U.S. participants. This group made up 76% of the trial’s enrolment, highlighting substantial national interest and the potential impact of larsucosterol.
✓ Small-Cap Stocks With Huge Potential
WELCOME BONUS - Free Share Bundle When You Invest £50!
Open a UK Investment Account: Shares, ISAs, Managed Portfolio
Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.
IG
View Offers
Empfohlener Broker
Multi Asset Platform
If you’re looking to add some small-cap stocks to your portfolio, then you need to see this.
Before you decide where to invest, you will want our special report on 5 Small-Cap Stocks To Consider. Our team of experts have picked our 5 small-cap stocks they think have the biggest potential for growth in 2024 and beyond.
What’s more, we’re giving away this valuable research FOR FREE!
Following the announcement, Northland has reiterated its positive outlook on Durect, underscoring that the Phase 3 trial set-up “uniquely derisks larsucosterol’s development.”
The financial firm maintains an Outperform rating on Durect shares, with a target price of $8.50. This endorsement from a major analytical firm might influence the market’s perception and investor sentiment towards Durect’s stock, as developments in pharmaceutical companies often do following significant regulatory milestones or promising trial results.
Searching for the Perfect Broker?
Discover our top-recommended brokers for trading or investing in financial markets. Dive in and test their capabilities with complimentary demo accounts today!
- IG Top-tier regulation – Read our Review
- eToro Wide range of instruments available to trade – Read our Review
YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY
